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Mitochondrial dysfunction is considered one of the major causative factors in the aging process, ischemia/reperfusion (I/R), septic
shock, and neurodegenerative disorders like Parkinson’s disease (PD), Alzheimer’s disease (AD), and Huntington’s disease (HD).
Increasedfreeradicalgeneration,enhancedmitochondrialinduciblenitricoxide(NO)synthaseactivity,enhancedNOproduction,
decreased respiratory complex activity, impaired electron transport system, and opening of mitochondrial permeability transition
pore all have been suggested as factors responsible for impaired mitochondrial function. Melatonin, the major hormone of the
pineal gland, also acts as an antioxidant and as a regulator of mitochondrial bioenergetic function. Both in vitro and in vivo,
melatonin was eﬀective for preventing oxidative stress/nitrosative stress-induced mitochondrial dysfunction seen in experimental
models of PD, AD, and HD. In addition, melatonin is known to retard aging and to inhibit the lethal eﬀects of septic shock or I/R
lesions by maintaining respiratory complex activities, electron transport chain, and ATP production in mitochondria. Melatonin
is selectively taken up by mitochondrial membranes, a function not shared by other antioxidants. Melatonin has thus emerged as
a major potential therapeutic tool for treating neurodegenerative disorders such as PD or AD, and for preventing the lethal eﬀects
of septic shock or I/R.
1.Introduction
Mitochondrial dysfunction is implicated in the etiology of
various diseases, such as neurodegenerative diseases, dia-
betes, cardiovascular disease, various forms of hepatic disor-
ders, skeletal muscle disorders, sepsis, and psychiatric disor-
ders [1–10]. Abnormalities in mitochondrial functions such
as defects in the electron transport chain (ETC)/oxidative
phosphorylation (OXPHOS) system, Krebs’s cycle enzymes,
and ATP production have all been suggested as the primary
causative factors in the pathogenesis of neurodegenerative
disorders and sepsis.
Impaired mitochondrial dysfunction is regarded as the
driving force for the ageing process [11]. Enhanced produc-
tion of reactive oxygen species (ROS) and possibly accumu-
lation of mitochondrial (mt) DNA mutations in postmitotic
cells are considered to be contributory factors to age-related
degeneration. Mitochondria not only generate ROS/reactive
nitrogen species (RNS) but are also the main target of their
actions [12]. As a result of this action, damage occurs in2 International Journal of Alzheimer’s Disease
the mitochondrial respiratory chain, thus producing further
increases in free radical generation, ultimately self-inducing
a vicious cycle [13].
During the last decade, a number of studies have demon-
strated that melatonin plays an eﬀective role in regulating
mitochondrial homeostasis. In addition to being a free
radical scavenger, melatonin reduces nitric oxide (NO) gen-
eration within mitochondria. It maintains the electron ﬂow,
eﬃciency of oxidative phosphorylation, ATP production and
bioenergetic function of the cell by regulating respiratory
complex activities, Ca2+ inﬂux, and mitochondrial perme-
ability transition pore opening [14–18].
In this article, the several mechanisms through which
melatonin exerts neuroprotective actions in neurodegener-
ative disorders such as Parkinson’s disease (PD), Alzheimer’s
disease (AD), and Huntington’s disease (HD) and in a num-
ber of mitochondrial dysfunction related conditions such
as aging, ischemia/reperfusion (I/R), or septic shock, are
reviewed. For another recent survey of literature see [19].
2. MitochondrialFunction and
FreeRadicalGeneration
Mitochondria contain multiple copies of a circular genome
(chromosome) known as mtDNA as it has been charac-
terized in humans [20]. Although the majority of mito-
chondrialproteinsessentialfornormalbioenergeticfunction
are encoded by nuclear DNA [21], some proteins needed
for ETC/OXPHOS are encoded by mtDNA. Human mito-
chondrial genome encodes for 13 peptides of subunits of
complexes I, III, and IV, and ATP synthase complex, 22
transfer RNAs and 2 ribosomal nucleic acids, while nuclear
DNA encodes for at least 1000 mitochondrial proteins [22].
TheprimaryfunctionofmitochondriaistogenerateATP
within the cell through the ETC resulting in OXPHOS. The
ETC,whichispresentintheinnermitochondrialmembrane,
comprises a series of electron carriers grouped into four
enzyme complexes, namely, complex I (NADH ubiquinone
reductase), complex II (succinate ubiquinone reductase),
complex III (ubiquinol cytochrome-c-reductase), and com-
plex IV (cytochrome c oxidase) [23].
T h em a i nf u n c t i o no ft h eE T Ci st oc o n v e r tr e d o xe n e r g y
into an electrochemical gradient of protons that subse-
quently causes ATP formation from ADP and phosphate
by ATP synthase. The end product of the respiratory chain
is water that is generated in a four-electron reduction of
molecular oxygen (O2) by complex IV. During this process
(electron leakage especially at complex I and III), a small
percentage of O2 is converted into ROS, such as superoxide
anion radical (O2
￿−) and its secondary products hydrogen
peroxide (H2O2) and reactive hydroxyl radical (￿OH) [23,
24]. Under normal conditions, the iron-sulfur cluster N2 of
complex I appears to be the primary source of free radicals in
the brain [23, 25].
Mitochondrial NO synthase (mtNOS) localized in the
inner mitochondrial membrane is responsible for generating
NO radical (￿NO) from L-arginine [26]. Localization of
mtNOS refers only to myristoylated nNOS splice variant
alpha, which is also relevant because of its interaction with
Complex IV. Because of NO diﬀusion, cytoplasmic NOS
forms are also relevant for generating ￿NO. High rates
of ￿NO synthesis, which typically occur in the calcium-
dependent excited state of neurons, can contribute to oxida-
tiveandnitrosativestress.Theavailabilityof ￿NOdetermines
the rates at which the adduct peroxynitrite (ONOO−)a n d
the decomposition products are generated.
The free radical ￿NO is produced by several forms of
NOS. In the mitochondria, two NOS isoforms, namely
constitutiveandinduciblehavebeenreported(c-mtNOSand
i-mtNOS). Since ￿NO is an uncharged gaseous compound,
it crosses membranes with ease and can enter mitochondria
regardless of their neuronal, glial, or vascular origin. ￿NO
strongly interferes with components of the respiratory chain,
in particular cytochrome C oxidase [27–29]. Its metabolite
ONOO− and radicals derived from this can damage proteins
of respiratory complexes. Other nitrosation processes, like
transnitrosation or reversible nitrosation and nitration as
well as irreversible protein and lipid oxidation, can occur.
Upon entering neuronal mitochondria, ￿NO, in com-
bination with ONOO− (formed there by combination
with O2
￿− from electron leakage), not only interferes with
respiratory chain complexes but, when it reaches elevated
levels, can trigger free radical-mediated chain reactions that
in turn destroy protein, lipid, and DNA molecules [30–32].
As it has been stated above, damage to the mitochondrial
respiratory chain can cause a breakdown of the proton
potential, apoptosis, or lead to further generation of free
radicals, thus maintaining a vicious cycle that ultimately
results in cell death [23, 33].
In the mitochondrial-mediated cell death pathway, a
nonspeciﬁc increase in the permeability of the inner mito-
chondrial membrane occurs, when mitochondrial matrix
calcium is greatly increased [34].Thisisknownasmitochon-
drial permeability transition (mtPT), a process associated
with the opening of channels in the inner mitochondrial
membrane,whichinturncausesaﬂuxofmoleculesof<1500
daltons [35].
Both Ca2+ and ROS are major mtPT regulators. The
inner mitochondrial membrane possesses a uniporter to
transport Ca2+ into the matrix. With Ca2+ overload, there is
complete uniporter inhibition, mitochondrial swelling, loss
of respiratory control, and a release of matrix calcium caused
by mtPT pore opening [35, 36]. Under these conditions, ATP
is hydrolyzed by mitochondria, the mitochondria undergo
swelling, and mitochondrial-mediated apoptosis occurs.
Free radicals are continually generated in cells during
normal activity. This process is essential for normal cellular
physiology [37]. A number of mechanisms take part in the
control of ROS/RNS production. Among these is the action
of the enzyme superoxide dismutase (SOD), which occurs in
the inner side of the inner mitochondrial membrane (Mn-
SOD), that remove O2
￿− [38]. ￿OH generated from H2O2 in
the presence of reduced transition metals are scavenged by
theenzymeglutathioneperoxidase(GPx),duringtheprocess
of metabolism of reduced glutathione (GSH) to its disulﬁde
(GSSG),whichinturnisreducedbacktoGSHbytheenzyme
glutathione reductase (GRd) [39].International Journal of Alzheimer’s Disease 3
These enzymes form part of the endogenous antioxidant
defense system and suppress ROS levels within the cell
as well as within the mitochondria. Antioxidants such as
ascorbate, ubiquinone, or α-tocopherol can participate in
the mitochondrial antioxidative defense system, but none of
t h e mc a nc o n v e r tO 2
￿− to O2.I ti sG S Ht h a tp a r t i c i p a t e si n
scavenging O2
￿−, as well as in several redox reactions and
maintains the mtTP pore closed. The redox cycling in the
mitochondria is very active and serves to prevent signiﬁcant
loss of GSH. This is important because the mitochondria
contain GPx and GRd activities and depend only on GSH
uptake from the cytoplasm to keep adequate GSH levels.
Since melatonin promotes de novo synthesis of GSH
by stimulating the activity of the enzyme γ-glutamyl-
cysteine synthetase [40] and also through its eﬀects on gene
expression of GPx, GRd, SOD, and CAT [41–45] helping in
the recycling of GSH and in maintaining high GSH/GSSG
ratio [46], the role it plays in mitochondrial physiology is
important [47].
3.Melatonin:Biosynthesis, Metabolism,
andReceptors
Melatonin was ﬁrst isolated and identiﬁed by Lerner and
coworkers in 1958 [48]. This methoxyindole is synthesized
and released to the circulation by the pineal gland. The
synthesis of melatonin that occurs in a number of other
tissues and cells does not contribute signiﬁcantly to the
circulating melatonin levels but rather exerts an autocrine or
paracrine role. Within this category, melatonin synthesis by
lymphocytes [49], skin [50], the gastrointestinal tract [51],
thymus [52], several parts of the eye [53]o rb o n em a r r o w
[54] should be mentioned.
Tryptophan serves as the precursor for the biosynthe-
sis of melatonin. It is converted into serotonin via 5-
hydroxytryptophan. Serotonin is then acetylated to form
N-acetylserotonin through the action of arylalkylamine N-
acetyltransferase, one of the key enzymes in melatonin
synthesis. N-acetylserotonin is then converted to melatonin
byhydroxyindole-O-methyltransferase(HIOMT),whichhas
been identiﬁed as a rate-limiting enzyme in the biosynthesis
of pineal melatonin [55, 56].
Once formed, melatonin is not stored within the pineal
gland but diﬀuses into the capillary blood and cerebrospinal
ﬂuid [57]. In a recent study conducted in humans, CSF
melatonin levels were found to be higher in the third
ventricle compared to the lateral one, thus indicating that
melatonin enters the CSF through the pineal recess, even
during daytime [58]. The brain has much higher concentra-
tions of melatonin than any other tissue in the body [59].
In the circulation, melatonin is partially bound to albu-
min [60] and can also bind to hemoglobin [61]. Circulating
melatonin is metabolized mainly in the liver where it is ﬁrst
hydroxylated by cytochrome P450 mono-oxygenases (isoen-
zymes CYP1B1, CYP1A2, CYP1A1) and, thereafter, conju-
gated with sulphate to be excreted as 6-sulfatoxymelatonin.
Under certain circumstances, 6-sulfatoxymelatonin may be
also synthesized in the brain. Melatonin can be metabolized
nonenzymatically in all cells of the body. It is converted into
3-hydroxymelatonin when it scavenges two ￿OH [62]. In the
brain, melatonin can be metabolized to kynuramine deriva-
tives [63], particularly under inﬂammatory conditions.
These metabolites of melatonin which are formed in the
brain, namely, N1-acetyl-N2-formyl-5-methoxy kynuramine
(AFMK) and N1-acetyl-5-methoxykynuramine (AMK), also
share the antioxidant and anti-inﬂammatory properties of
melatonin [64, 65].
Melatonin is involved in the control of various phys-
iological functions of the body such as seasonal control
of reproductive processes [66, 67], sleep regulation [68],
immune mechanisms [69, 70], and regulation of circadian
[71, 72] and sleep-wake rhythms [73, 74]. In addition to the
above-mentioned physiological actions, melatonin in phar-
macological doses inhibits tumor growth and may have a
potential therapeutic value in treating breast cancer, prostate
cancer,melanoma,andcancerofGItract[75,76].Melatonin
also exerts antinociceptive and antiallodynic actions [77]. As
the prototype of the chronobiotic class of drugs [74, 78–80],
melatonin regulates the phase and amplitude of circadian
rhythmicity by interaction with MT1 and MT2 receptors
expressedinthehypothalamicsuprachiasmaticnuclei(SCN)
and other brain areas.
Melatonin exerts many of its actions via membrane
receptors,namely,MT1 andMT2 receptorsthatareexpressed
both singly and together in various tissues of the body
[81–83]. A third melatonin binding site that was isolated
and puriﬁed from hamster kidney has been characterized
as quinone reductase type 2 [84]. This enzyme belongs to a
group of reductases that participate in the protection against
oxidative stress by preventing electron transfer reactions of
quinones. Melatonin is also a ligand for retinoid orphan
nuclear receptors [85–87].
The melatonin MT1 receptor is coupled to diﬀerent G
proteins that mediate adenylyl cyclase inhibition and phos-
pholipase C activation [83]. The MT2 receptor is coupled to
a number of signal transduction mechanisms among them
phosphoinositide production, inhibition of adenylyl cyclase,
and inhibition of guanylyl cyclase [83].
4.Melatonin’sFree RadicalScavenging
andAntioxidantActions
Because of its amphiphilic properties, melatonin passes
through all biologic barriers with ease. Melatonin gets access
freely to all compartments of the cell, and can be especially
concentrated in the nucleus and mitochondria [15, 47, 88].
The discovery that melatonin was a remarkably potent
scavenger of the particularly reactive, mutagenic, and car-
cinogenic ￿OH [89] was the ﬁnding that initiated numerous
studies on melatonin’s role as a protector against free
radicals. Melatonin was shown to be much more speciﬁc
than its structural analogs in undergoing reactions which
lead to the termination of the radical reaction chain and
in avoiding pro-oxidant, C- or O-centered intermediates
[89–91]. Moreover, melatonin scavenged numerous diﬀerent
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carbonate radical [92]i si m p o r t a n tb e c a u s eo fi t sp r e s u m e d
role in mitochondrial damage [93].
Although direct radical scavenging has been eﬀective
under numerous experimental conditions at clearly sup-
raphysiological melatonin concentrations, its relevance at
physiological levels has been questioned for reasons of
stoichiometry.Eventhoughasinglemelatoninmoleculemay
generate products in a scavenger cascade which may collec-
tively eliminate up to ten free radicals [94], such ﬁndings
from chemical systems may not be fully applicable to physi-
ological conditions.
In spite of this criticism, melatonin has been shown
to protect from oxidotoxicity already at physiological con-
centrations [95]. A possible indirect action as mediated by
upregulation of antioxidant enzymes by melatonin was
proposed (reviewed in [96, 97]).
An alternate concept has been put forth to explain the
protective eﬀect at the level of radical generation rather
than detoxiﬁcation of already formed radicals [98–100]. If
melatonin is capable of decreasing the processes leading
to enhanced radical formation, this might be achieved by
low, physiological, concentrations of the methoxyindole.
Apart from oxidants released by leukocytes, the isoforms
of NAD(P)H oxidases (Nox) and mitochondria should be
mentioned as main sources of free radicals in the cell.
Nox isoenzymes contribute to superoxide formation in a
quantitatively substantial manner [101–104]. A recent study
showed that melatonin inhibits free radical formation
in microglia exposed to amyloid-β1–42 by preventing the
phosphorylation of the p47 Nox subunit via the PI3K/Akt
pathway [105] thus giving support to the hypothesis that
melatonin has a protective eﬀect at the level of radical
generation.
5. MelatoninandMitochondrial Function
Melatonin’s ability to inﬂuence mitochondrial function has
been tested both in vivo and in vitro. In initial in vivo studies
conducted on rats, ETC complexes from the mitochondria
of brain and liver tissues were measured following injections
of melatonin (10mg/kg). Melatonin was found to increase
the activity of C-I and C-IV of mitochondrial ETC in a
time-dependent manner, C-II and C-III not being aﬀected.
The eﬀect of melatonin was observed 30min after melatonin
treatment [15]. Ruthenium red was found to impair mito-
chondrial metabolism by reducing ETC and ATP synthesis
through its cellular oxidative stress action. Inhibition of both
C-I and C-IV of the ETC were noted. Injections of melatonin
were found to counteract the inhibitory eﬀect of ruthenium
red on C-I, C-IV, and GPx enzyme [15].
In an in vitro study, the eﬀect of melatonin on t-butyl
hydroperoxide- (t-BHP-) induced mitochondrial oxidative
stress was evaluated. t-BHP depletes mitochondrial GSH and
inhibits GPx and GRd activities [106]. In mitochondrial
preparations, 100nM melatonin was found to prevent the
oxidation of GSH to GSSG induced by t-BHP and also
restored the normal activities of both GPx and GRd [14].
Melatonin increased C-I and C-IV in a dose-dependent
manner, the eﬀect being signiﬁcant at 1nM. Melatonin also
counteracted cyanide-induced inhibition of C-IV showing
thereby that melatonin can increase the activity of ETC
coupled to OXPHOS and increase ATP synthesis in normal
mitochondria as well as in mitochondria depleted of ATP
by cyanide [14]. The eﬀects of melatonin in regulating
ComplexesIandIVpresumablydonotreﬂectitsantioxidant
role but indicates an interaction with ETC complexes by
donatingandacceptingelectrons,therebyincreasingelectron
ﬂow, an eﬀect not shared by other antioxidants.
The major consequence of melatonin’s action on mito-
chondria may be avoidance of damage and dysfunction
thus contributing to increase ATP production [16, 107].
Melatonin increases the eﬃciency of ETC thereby limiting
electron leakage and free radical generation, and conse-
quently promoting protein synthesis [17, 47].
The possible mechanism by which melatonin controls
mitochondrial respiration in the liver was examined in
two groups of rats [108]. In one group, melatonin (16 to
50μg/mL) or vehicle was administered for a period of 45
days. In another study, rats received melatonin in drinking
water (50μg/mL) for 45 days or the same amount for 30
days, followed by a withdrawal period of 15 days. At sacriﬁce,
the liver mitochondrial fraction was prepared and oxygen
consumptionwasmeasuredinthepresenceofexcessconcen-
tration DL-3 β-hydroxybutyrate or L-succinate. Melatonin
treatment decreased Krebs’s cycle substrate-induced respira-
tion signiﬁcantly at both examined doses. The stimulation of
mitochondrial respiration, caused by excess concentration of
substrate,recoveredaftermelatonin withdrawal.Basalstate4
respiration was not modiﬁed by melatonin. This study shows
that melatonin can protect mitochondria from oxidative
damageresultingfromoverstimulationofcellularrespiration
caused by excess Krebs’ cycle substrate [108].
A similar study on melatonin’s mechanism of action
on mitochondrial respiration was carried out by another
group of investigators [18]. In this study, mitochondria from
mouse liver cells was incubated in vitro with melatonin
at concentrations ranging from 1nM to 1mM. Melatonin
decreased oxygen consumption, inhibited the increase in
oxygen ﬂux in the presence of excess of ADP, reduced mem-
brane potential and inhibited the production of O2
￿− and
H2O2. Melatonin was also able to maintain the eﬃciency of
oxidative phosphorylation and ATP synthesis by increasing
the activity of the respiratory complexes I, III, and IV. These
eﬀects were attributed to the intramitochondrial presence
of melatonin, thus showing melatonin’s participation in the
physiological regulation of mitochondrial homeostasis [18].
Melatonin’s action in preventing the opening of the
mtPT pore given by oxidative stress caused by t-BHP was
shown in another study on primary skeletal muscle cultures
[109]. Using isolated mitochondria, melatonin (1–100μM)
fully prevented myotube death induced by t-BHP. Melatonin
desensitized the mtPT pore to Ca2+ and prevented t-BHP-
induced mitochondrial swelling and GSH oxidation. The
inhibition of the mtPT pore opening by melatonin was
suggested as an explanation for the protective action of
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Recently, the role of melatonin on cardiolipin and mito-
chondrialbioenergeticswasexplored[110,111].Cardiolipin,
a phospholipid located at the level of inner mitochondrial
membrane, is required for several mitochondrial bioen-
ergetic processes as well as in mitochondrial-dependent
steps of apoptosis. Alterations in cardiolipin structure,
content, and acyl chain composition have been associated
with mitochondrial dysfunction in various tissues under a
variety of pathophysiological conditions [110]. Melatonin
was reported to protect the mitochondria from oxidative
damage by preventing cardiolipin oxidation and this may
explain, at least in part, the beneﬁcial eﬀect of this molecule
in mitochondrial physiology [110, 111].
5.1. Melatonin and Mitochondrial Dysfunction in Aging. The
enhanced production of ROS and accumulation of mtDNA
mutations in mitochondria may be contributory factors to
human aging [112]. Many studies have established that the
respiratoryfunctionofmitochondriadeclineswithage[113–
115]. The increased production of free radicals such as O2
￿−
and H2O2 in mitochondria along with advancing age has
been demonstrated [116, 117]. Accumulation of mtDNA
mutations can cause defective respiratory function resulting
in enhanced production of ROS. Many of these mtDNA
mutations begin after adults reach their the mid thirties and
accumulate with age in postmitotic tissues [115].
Overproliferation of abnormal mitochondria has been
shown to occur in the muscle of aged individuals and in
patients with mitochondrial myopathies [115, 118]. The
presence of these defective mitochondria is one of the factors
involved in the decline in respiratory function during the
aging process [115].
Enhanced activation of the mtPT pore in the brain and
liver of aging mice has also been demonstrated [119]. This
in turn causes the release of proapoptotic factors from the
intermembrane space of mitochondria. Hence, an increased
mitochondrial ROS production, oxidative stress, respiratory
functional decline, and susceptibility to apoptosis constitute
central events in the aging process [115].
The mechanism of the aging process can be studied in
experimental models like the senescence accelerated mouse
(SAMP8) and senescence resistant mouse (SAMR1). The
SAMP8 is an established murine model of accelerated
aging [120]. The accelerated aging seen in this mouse
strain is due to oxidative stress, which occurs with greater
intensity as compared to the SAMR1 [121]. At an age of 12
months, reductions in the activities of respiratory complexes
I and IV have been demonstrated in liver mitochondria
of SAMP8 mice, but not in SAMR1 mice [122]. Greater
concentrationsoflipidperoxidationproductsintheliverand
brain homogenates were found in SAMP8 mice as compared
to SAMR1 mice. In contrast to this, the concentration of the
antioxidant enzyme GPx from SAMP8 mice at 12 months of
age was found to be signiﬁcantly lower than in SAMR1 mice.
These studies support the conclusion that excess free radical
generation coupled with less eﬀective defense against the
oxidative stress is responsible for alteration of mitochondrial
function seen in SAMP 8 mice [122–124].
Since melatonin can readily reach the mitochondria
due to its high lipophilicity, it seems feasible that, upon
its entry into the cell, it could become concentrated at a
superﬁcial position in lipid layers near the polar heads of
membrane phospholipids, a key place to function as a free
radical scavenger [125]. The eﬀect of melatonin on age-
dependentchangesintheredoxstatusofmitochondriainthe
heart and diaphragm was thus evaluated [126]. Melatonin,
administered in the drinking water at a dose of 10 mg/kg for
9 months, was shown (i) to counteract the age-dependent
increase in lipoperoxidation level, (ii) to increase GSH
contentinmusclemitochondria ofbothSAMP8andSAMR1
mice, (iii) to counteract the reduction of GSH/GSSG ratio in
diaphragmatic mitochondria of SAMR1 and SAMP8 mice,
(iv) to increase the activity of the antioxidant enzymes GPx
and GRd in the mitochondria of SAMP8 mice with no eﬀect
on SAMR 1 mice, and (v) to increase the activity of GRd
in SAMR1 mice. Therefore, long-term melatonin adminis-
tration prevented the age-dependent mitochondrial stress in
both senescence-accelerated and senescence-resistant mice
[126].
As a continuation of the above-mentioned study, the
eﬀect of melatonin at earlier stages of the life span was
evaluated at the 5th and 10th months of age in SAMP8
and SAMR1 mice [127]. Mitochondrial oxidative stress was
determined by measuring the levels of lipid peroxidation,
GSH and GSSG, and the activities of GPx and GRd in
diaphragmatic mitochondria. Age did not aﬀect diaphrag-
matic mitochondrial levels of lipid peroxidation in SAMR1
mice but increased them in SAMP8 animals. When mela-
tonin was administered in the drinking water at a daily dose
of 10 mg/kg, the level of lipid peroxidation in 10-month-old
SAMP8 mice was reduced to that found at 5 months of age.
The decrease of GPx seen with age in both strains of mice
was counteracted by melatonin administration with a higher
eﬀect in SAMP8 mice. As far as GRd, although age caused
signiﬁcant reductions in both strains of mice, treatment with
melatonin partially restored GRd activity in SAMR1 mice
only. The chronic administration of melatonin signiﬁcantly
increased complex II and complex III activity in SAMR1 and
SAMP8miceandcomplexIVactivityinSAMP8mice[127].
Measurement of ATP levels and ATP/ADP ratio showed
that treatment with melatonin counteracted the reduction
in ATP levels and ATP/ADP ratio found in SAMP8 mice.
As far as longevity, melatonin treatment increased the half-
l i f eo fS A M P 8m i c ef r o m1 6t o2 2m o n t h sw h i l el o n g e v i t y
increased from 23 to 27 months [127]. Melatonin’s beneﬁcial
eﬀects on longevity were signiﬁcantly higher in SAMP8 mice
than in SAMR1 mice. The study thus showed that melatonin
administration counteracted age-dependent oxidative dam-
age and mitochondrial dysfunction in senescence accelerated
mice by improving mitochondrial function as reﬂected by
the increase in ATP production and a prolonged longevity
[127].
Another study using rat brain mitochondria was de-
signed to evaluate the beneﬁcial eﬀects of melatonin on
age-associated reductions in mitochondrial bioenergetic
function [111]. Mitochondria from control and aged rats
treated or not with melatonin were obtained, and various6 International Journal of Alzheimer’s Disease
bioenergetic parameters such as complex I activity, rates of
state 3 respiration, mitochondrial H2O2 production, and
membrane potential were evaluated. Melatonin was found to
prevent the signiﬁcant age-related changes that occurred in
all of these parameters in untreated animals. The ability to
prevent complex I dysfunction and cardiolipin peroxidation
was melatonin’s principal mechanism of action for achieving
its eﬀects [111].
Age-associated impairments in mitochondrial OXPHOS
found in the brain of SAMP8 mice did not exhibit any major
gender diﬀerences [128]. However, a higher reduction in the
GSH/GSSG ratio at 10 months of age in female than in male
SAMP8 mice has been reported in one study [129]. Chronic
melatonin treatment completely prevented age-dependent
oxidative stress as assessed by the recovery of the GSH/GSSG
in mitochondria of brain samples of both male and female
mice [129]. The ability of melatonin to prevent GSH loss
with age probably reﬂects its inﬂuence on the activities of the
GSH redox cycle enzymes [47].
An impairment of the mitochondrial respiratory chain
activity occurs with age. This is not due to reduction of brain
mitochondria with aging but has been demonstrated to be
due to diminished activities of respiratory complexes I, II,
andIII[130].Mitochondrialdysfunctionwithagingisnotan
irreversible process as shown by studies using melatonin to
prevent age-dependent declines in bioenergetic impairment
of brain mitochondria in mice [129].
5.2.M elatoninandM itochondrialF unctioninI/R. I/Rlesions
are seen in many clinical conditions and are triggered by
multiple factors including overproduction of ROS [131–
133]. For example, ROS produced at the level of complex I
andIIIoftherespiratorychainareresponsibleforinjuryseen
in cardiac I/R [134, 135]a sw e l la si ns t r o k e[ 133].
The available evidence indicates the opening of the mtPT
pore is responsible for the cardiomyocyte death occurring
during I/R [136]. While these pores remain closed during
the ischemic period, at reperfusion the inﬂux of Ca2+
into the mitochondria and an associated burst of ROS
production caused the opening of mtPT channels. This leads
to mitochondrial depolarization, swelling, and rupture of
the external mitochondrial membrane, with uncoupling of
the respiratory chain and eﬄux of cytochrome C and other
proapoptotic factors, all of which lead to either cell death by
either apoptosis or necrosis.
Melatonin has also been shown to be eﬀective in pro-
tecting the cardiac musculature against I/R [137–139].
Melatonin’s protective eﬀect during I/R has been attributed
to its action in inhibiting the mtPT pore [140], and in
preserving the content and integrity of cardiolipin molecules
[141]. Melatonin treatment resulted in signiﬁcant reductions
in infarct size [142].
The fact that melatonin treatment inhibits both mtPT
pore opening and cardiolipin peroxidation following I/R
suggests a possible link between these two processes. It has
been suggested that that increased levels of peroxidized
cardiolipin together with increased Ca2+ overload can con-
tribute to the mtPT pore opening during reperfusion [143].
Melatonin, by preventing the oxidative damage of cardi-
olipin,preventsmtPTchannelopening.Itmustbenotedthat
a signiﬁcant cytoprotective eﬀect of melatonin was described
ataveryearlyphaseofamyocardialinfarction,whenI/Rand
thus oxidative damage were minimal [144], indicating that
not all cardiac protective eﬀects of melatonin are attributable
to its antioxidant activity.
5.3. Melatonin and Mitochondrial Dysfunction in Sepsis.
Septic shock is a lethal condition caused by a complex chain
of pathogen-induced events involving immune cells, the
epithelium, the endothelium, and the neuroendocrine sys-
tem. The lethal eﬀects of septic shock are associated with
the production and release of numerous proinﬂammatory
mediators as well as NO and ROS, thus inducing massive
apoptosis.
Since many years ago, research interest was focused on
thehypothesisthatmitochondrialdysfunctionplaysapivotal
role in septic shock. This hypothesis was indeed conﬁrmed
bytheﬁndingofdecreasedrespiratorycomplexIactivityand
low levels of ATP levels in skeletal muscle biopsies obtained
from critically ill patients with septic shock [145]. Increased
NO production and decreased levels of GSH were also found
in septic shock patients.
The protective eﬀect of melatonin on the lethal eﬀects
of bacterial lipopolysaccharide (LPS) on respiratory complex
activities I and IV and a mitochondrial subform of iNOS (mt
iNOS) activity was examined in liver and lung mitochondria
of rats [146]. LPS administered at a dose of 10mg/kg i.v.
was found to increase mt iNOS activity and NO, an eﬀect
that was greater in old rats than in young ones. LPS also
decreased the activities of respiratory complexes I and IV.
Melatonin administration (60mg/kg, i.p.) prevented LPS
toxicity by decreasing mt iNOS activity and NO production.
It also counteracted LPS-induced inhibition of the activity
of respiratory complexes I and IV. It is interesting to
note that the eﬀectiveness of melatonin to prevent the
mitochondrial failure that occurs during endotoxemia were
morepronouncedinolderanimalsthaninyoungones[146].
Using a long-term (3-day) rat model of sepsis, a number
of parameters of mitochondrial dysfunction were investi-
gated. The model comprises a long-term, ﬂuid-resuscitated,
fecal peritonitis model utilizing male Wistar rats that
closely replicates human physiological, biochemical, and
histological ﬁndings with a 40% mortality [8]. Compared to
sham-operated controls severely septic rats had lower (20–
22%) hepatic and muscle complex I activities. Moderate
increases in nitrite/nitrate production were seen in both
muscle and liver peaking at 24–48h and returning to sham-
operated levels at 72h. A fall in GSH was associated with
lower complex I and increased NO production was also
demonstrated [8]. A number of animal model studies and
a few clinical observations have now shown that melatonin is
beneﬁcial for treating septic shock (see, for a recent review,
[147]).
To examine the eﬀect of melatonin on changes in mt
iNOS in septic skeletal muscles wild-type (iNOS+/+)a n d
iNOS knockout (iNOS−/−) mice were turned septic by theInternational Journal of Alzheimer’s Disease 7
cecal ligation and puncture procedure [148]. After sepsis,
increases in mt iNOS and NO levels, and decreases in
electron chain activity were noted in iNOS+/+ mice but
not in iNOS−/− mice. In addition, an increase in oxidative
stress was also found as indicated by an increase in lipid
peroxidation products as well as a reduction in GSH levels
and in the activities of GPx and GRd. Melatonin treatment
counteracted the changes in mt iNOS activities and oxidative
stress, and, further, restored the mitochondrial respiratory
c h a i ni ni N O S +/+ mice [148]. This study conﬁrmed that
mtNOS is responsible for the mitochondrial dysfunction
seen during sepsis and thus supported the conclusion that
melatonin has the ability to protect against mt iNOS-
mediated mitochondrial failure. A similar study performed
in mitochondria isolated from the diaphragm of septic
mice indicated that melatonin administration to iNOS+/+
mice counteracted mt iNOS induction and respiratory chain
failure, and, ﬁnally, normalized the redox state after sepsis
[149].
Considering the eﬀects of melatonin and its virtual
absence of toxicity, the use of melatonin along with con-
ventional therapy to preserve mitochondrial bioenergetics as
well as to limit inﬂammatory response and oxidative damage
should be taken into account as a treatment option [147].
5.4. Melatonin and Mitochondrial Dysfunction in PD. PD is
a neurodegenerative disorder with a multifactorial etiology,
mainly characterized by the death of dopaminergic neurons
in the pars compacta of substantia nigra and by the forma-
tion of Lewy bodies. The initiating factor in PD is increased
release of free radicals and enhanced signs of oxidative stress
as demonstrated in brains of PD patients [150–152].
Although the molecular mechanisms responsible for the
pathogenesis of AD are still under intense investigation
[128], reduced complex I activity in the substantia nigra
[153] and loss of GSH [154]h a v eb e e nr e p o r t e di nP D
patients. The selective inhibition of complex I in the ETC
compromises energy availability and leads to apoptosis and
death of the dopaminergic cells of substantia nigra.
A commonly accepted model of PD is that achieved by
the systemic or intracerebral administration of neurotoxins
like 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP).
The loss of dopamine neurons occurring in these animal
models causes severe sensory and motor impairment which
in turn gives rise to tremor, rigidity and akinesia similar
to those seen in PD patients [155, 156]. The active glial
metaboliteofMPTP,1-methyl-4-phenylpyridinium(MPP+),
is taken up into the dopaminergic neurons through the
dopamine transporter, and then accumulates in the mito-
chondriaofsubstantianigraparscompacta[157].Bybinding
to complex I, MPP+ increases the production of ROS and
enhancesoxidativestresscausingreductionofATPanddeath
of cells in the substantia nigra [157].
Inthestriatum,thedamagecausedbyMPP+ isattributed
to increased generation of O2
￿− that reacts with NO to gen-
erate the highly toxic ONOO−. This impairs mitochondrial
function as a result of irreversible inhibition of all ETC
complexes [158] leading to the death of neuronal cells [159].
An e u r o p r o t e c t i v ee ﬀect of melatonin in isolated rat
striatal synaptosomes and liver mitochondria treated with
MPP+ has been demonstrated [160]. Melatonin prevented
the inhibition of mitochondrial respiration by limiting the
interaction of MPP+ with complex I of ETC.
Although the role of ROS generation has been demon-
strated in the etiology of PD, the participation of mtNOS
in the mitochondrial dysfunction and nigrostriatal degen-
eration has only recently been examined [128]. In a study
conducted in adult male mice, MPTP was administered at a
dose of 15mg/kg in four separate doses [161]. Animals also
received melatonin or its metabolite AMK (20mg/kg) 1h
prior to MPTP injection. The administration of melatonin
or AMK concomitantly with MPTP signiﬁcantly reduced the
iNOS activity stimulated by MPTP.
In the mitochondria, two NOS isoforms, namely, consti-
tutive and inducible, may exist. MPTP administration signif-
icantly increased the activity of mt iNOS without aﬀecting
mt constitutive NOS activity. Treatment with melatonin or
AMK restored the basal activity of i-mtNOS. Interestingly,
MPTP administration induced i-mtNOS activity in the
mitochondria of substantia nigra whereas i-mtNOS was
only slightly induced by MPTP in striatal mitochondria.
Treatment with either melatonin or its brain metabolite
AMK eﬀectively counteracted i-mtNOS induction, oxidative
stress, and mitochondrial dysfunction induced by MPTP
[161]. The nitrosative/oxidative stress reduction seen after
therapeutic intervention with melatonin or AMK in MPTP
treated micewasattributed to an eﬀectin preventing damage
to mitochondria. As already mentioned, mitochondria take
up melatonin in a concentration- and time-dependent
manner [18].
A small number of controlled trials indicate that mela-
tonin is useful to treat disturbed sleep in PD [162, 163],
particularly rapid eye movement-associated sleep behavior
disorder [164–169]. Whether melatonin or the recently
introduced melatonergic agents (ramelteon, agomelatine)
have the potential for treating insomnia in PD patients and,
more generally, for arresting the progression of PD merits
further investigation.
5.5.M elatoninandM itochondrialDysfunctioninAD . Several
recent studies have conﬁrmed the involvement of mitochon-
drial ROS production and abnormal mitochondrial function
inthepathophysiologyofAD[170–177].ADischaracterized
by extracellular senile plaques of aggregated β-amyloid
(Aβ) and intracellular neuroﬁbrillary tangles that contain
hyperphosphorylated tau protein. The resulting clinical
eﬀect is a progressive loss of memory and deterioration of
cognition.
Aβ is reported to accumulate in subcellular compart-
ments and to impair neuronal function [178]. There is
substantial evidence to prove that mitochondrial toxicity
is linked to the progressive accumulation of mitochondrial
Aβ [179]. In the early phase of AD, inhibitors of β and γ-
secretase can be therapeutically eﬀective to halt AD disease
progression by inhibition of the protein misfolding of Aβ
into neurotoxic oligomeric aggregates.8 International Journal of Alzheimer’s Disease
Table 1: Melatonin activity in bioenergetic functions: evidence from in vitro and in vivo studies.
Animal model studies
( i nv i t r oa n di nv i v o ) Pretreatment Posttreatment with melatonin Reference(s)
Ruthenium red-eﬀect on
ETC system
Inhibition of complex I and IV and
impairment of ATP synthesis
Counteracted ruthenium red’s
inhibitory action complex I and IV [15]
t-BHP treated mitochondrial
preparations
Depletion of mitochondrial GSH;
inhibition of GPx and GRd activities
Prevented the oxidation of GSH to
GSSG, restored GPx and GRd back to
normal
[14]
MPTP eﬀect on isolated
striatal synaptosomes and
liver mitochondria
Inhibition of ETC complex I Prevented MPTP-induced inhibition
of complex I [160]
SAMP-8 mice Elevated lipid peroxidation products Reduced lipid peroxidation [122]
LPS-injected rats Increased mitochondrial NOS. NO
decreased ETC complex I and IV
Decreased NO production and
counteracted LPS-induced inhibition
of complex I an IV
[146]
Ischemia-reperfusion eﬀect
on mitochondria
Opens mtPT pores and destroys
cardiolipin in mitochondria
Inhibits mtPT pore opening and
preserves the structural complex of
cardiolipin in mitochondria
[140]
Mitochondria from heart
and diaphragm muscle of
SAMP-8 mice
Increased LPO; decrease in GSH
levels and GPx and GRd activities
Counteracted age-dependent
increase in LPO and reduction of
GSH, GPx, and GRd
[125]
Skeletal muscle of septic
wild-type (iNOS+/+)a n d
iNOS knockout (iNOS−/−)
mice
Increase of mt iNOS and NO levels,
increase of lipid peroxidation
products, decrease of GSH levels and
of GPx and GRd activities
Decreased mt iNOS and NO levels,
counteracted reduction of GSH, GPx
and GRd
[148]
Diaphragmatic muscle of
septic wild type (iNOS+/+)
and iNOS knockout
(iNOS−/−) mice
Increase of mt iNOS and NO levels,
r e d u c t i o no fG S Ha n do fG P xa n d
GRd activities
Decreased mt iNOS and NO levels;
counteracted reduction of GSH, GPx,
and GRd
[149]
Mitochondria from rat liver Normal ETC function
Melatonin treatment decreased
Krebs’s cycle substrate-induced
respiration.
[108]
Heart and diaphragmatic
muscle of SAMP-8 mice
Decreased levels of GSH and of GPx
and GRd activities, increased lipid
peroxidation
Increased GSH levels and GPx and
GRd activities; decreased lipid
peroxidation products
[126]
Diaphragmatic muscle of
SAMP-8 mice-eﬀect of aging
Decrease of GSH and GPx, GRd,
increase in lipid peroxidation
Counteracted age-dependent
decrease in GSH, GPx, and GRd
Normalized lipid peroxidation
[127]
Mitochondria from liver of
normal mice
Normal function of ETC complexes;
opening of mtPT pores after
oxidative stress
Increased complex I, III, and IV;
closing of the mtPT pores opened by
oxidative stress
[18]
t-BHP eﬀect on
mitochondria of skeletal
muscle
Opening of mtPT and death of
myotubules
Prevented t-BHP-induced opening of
mtPT pores and swelling of
mitochondria
[109]
MPTP eﬀect on
mitochondria of neurons in
substantia nigra of mice
Increased mt iNOS; increased
oxidative stress
Counteracted MPTP-induced
increase of iNOS in substantia nigra
and reduced the oxidative stress
[161]
Eﬀect of
ischemia-reperfusion on
mitochondria
Opening of mtPT pores and
oxidation of cardiolipin
Inhibited mtPT pores and cardiolipin
oxidation [110, 143]
Eﬀect of Aβ on hippocampal
neurons
Inhibition of ETC; reduced ATP
levels
Attenuated Aβ-induced inhibition of
respiratory complexes; restored ATP
levels
[187]
Abbreviations used: Aβ: β amyloid; ETC: electron transport chain; GPx: glutathione peroxidase; GRd: glutathione reductase; GSH: reduced glutathione;
GSSG: oxidized glutathione; iNOS: inducible nitric oxide synthase; LPS: lipopolysaccharide; MPTP: 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine; mt iNOS:
mitochondrial inducible nitric oxide synthase; mtPT: mitochondrial permeability transition; NO: nitric oxide; SAMP-8 mice: senescence accelerated mouse;
t-BHP: t-butyl hydroperoxide.International Journal of Alzheimer’s Disease 9
Mitochondrial O2
￿− production plays a critical role in
the pathological events following Aβ elevation. An increased
expression of mitochondrial antioxidant enzyme SOD-2
has been shown to prevent memory deﬁcits and amyloid
plaque deposition associated with AD [172]. Although a
hypotheticaloccurrenceofmutationsinmtDNAcouldcause
increased oxidative stress and energy failure, no causative
m u t a t i o n si nm t D N Ah a v eb e e nd e t e c t e di nA Ds of a r[ 180].
Several actions of melatonin have been described which
antagonize the deleterious eﬀects of Aβ. The eﬀects of
melatonin can be grouped as (i) antioxidant, including
inﬂuences on mitochondrial metabolism; (ii) antiﬁbrillo-
genic, blocking Aβ synthesis; (iii) cytoskeletal, including
suppression of tau protein hyperphosphorylation (for a
recent review see [181]). The antiﬁbrillogenic eﬀects of
melatonin were observed not only in vitro but also in vivo
in transgenic mouse models [182–184]. Protection from Aβ
toxicity was observed, especially at the mitochondrial level.
Melatonin also activates the survival signal pathways.
One such pathway is the Bcl-2 pathway, which stabilizes
mitochondrial function by antiapoptotic Bcl-2 family mod-
ulators. Bcl-2-expression was enhanced by melatonin con-
comitantly with inhibition of Aβ-induced cell death [185].
This in vitro study was mimicked by an in vivo one.
Melatonin inhibited free radical formation in microglia
exposed to amyloid-β1–42 by preventing the phosphorylation
of the p47 Nox subunit via the PI3K/Akt pathway [105].
In view of the consequences of excitation-dependent
calcium overload on mitochondrial membrane potential
and mtPT pore sensitivity towards excitotoxins like Aβ, the
actions of melatonin at the level of this important cellular
compartment deserve particular attention. Modulation of
mitochondrial Ca2+ handling has been suggested as the
potential pharmacological target for AD [186]. In a recent
study,apossiblemelatoninpreventionofdamageinducedby
Aβ was evaluated in young and senescent hippocampal neu-
rons. Rat hippocampal neurons were incubated with Aβ25–35
and cell viability, mitochondrial membrane potential, ATP,
and the activity of the respiratory chain complexes were
measured [187]. Cells exposed to Aβ25–35 showed decreased
mitochondrial membrane potential, inhibited activity of
respiratory chain complexes, and a depletion of ATP levels.
Melatonin attenuated Aβ25–35-induced mitochondrial dam-
age in senescent hippocampal neurons [187]. Molecular
studies undertaken with mitochondrial preparations suggest
that melatonin has a therapeutic value in treating AD
through its antiapoptotic activities [188].
As outlined, melatonin acts at diﬀerent levels relevant to
the development and manifestation of AD. The antioxidant,
mitochondrial, and antiamyloidogenic eﬀects may be seen
as a possibility of interfering with the onset of the disease.
Therefore, early beginning of treatment may be decisive
[189]. Mild cognitive impairment (MCI) is an etiologically
heterogeneous syndrome characterized by cognitive impair-
ment shown by objective measures adjusted for age and
education in advance of dementia [190]. Some of these
patients develop AD. A small number of controlled trials
indicate that melatonin is useful to treat MCI and to prevent
progression to AD [181, 191–194].
5.6. Melatonin and Mitochondrial Dysfunction in HD. A
Huntington’s chorea animal model was developed by using
3-nitropropionic acid, an inhibitor of mitochondrial com-
plex II. In this model, that replicates the neurochemical, his-
tological, and clinical features of HD, melatonin administra-
tionwasreportedtodefertheclinicalsignsofHD[195].Cur-
rentevidencefromgeneticmodelsofHDincludingmutation
of the huntingtin gene (mHtt), supports the mitochondrial
dysfunction as major cause of the disease, with respiratory
chain impairment relegated to a late secondary event [196].
Upstream events include defective mitochondrial calcium
handling and impaired ATP production. Also, transcription
abnormalities aﬀecting mitochondria composition, reduced
mitochondria traﬃcking to synapses, and direct interference
with mitochondrial structures enriched in striatal neurons,
are possible mechanisms by which mHtt ampliﬁes striatal
vulnerability [196]. Evidence is lacking on whether mela-
tonin’s action on mitochondria could aﬀect evolution in
the genetic model of HD. At least on the accumulation
of insoluble protein aggregates in intra- and perinuclear
inclusions in HD melatonin had little or no inhibitory eﬀect
on huntingtin aggregation [197].
6. Conclusions
Mitochondrial dysfunction is implicated as the major
causative factor in a variety of conditions such as the aging
process, I/R, and septic shock. In addition, abnormal mito-
chondrial function, decreased respiratory enzyme complex
activities, increased electron leakage, opening of the mtPT
pore, and increased Ca2+ entry have all been shown to play
a role in the pathophysiology of neurodegenerative disorders
such as PD, AD, and HD.
In addition to aging as a factor for low melatonin levels,
it is well documented that there is a huge interindividual
variation in circulating levels of melatonin which is stable
within individuals and, which has been hypothesized to
be genetic in origin [198–201] .T h e r ei sn o we v i d e n c e
that there are polymorphisms in the gene for HIOMT,
the rate limiting enzyme in melatonin synthesis, and that
the HIOMT transcript level depends signiﬁcantly on the
genotype distributions [202]. Thus, there may be a genet-
ically determined low melatonin syndrome that causes a
predisposition to a variety of diseases.
Among the number of substances involved in maintain-
ing mitochondrial bioenergetics a number of in vivo and
in vitro studies in animals (Table 1) indicate that melatonin
may emerge as a major therapeutic candidate to preserve
the bioenergetic function of mitochondria. Double-blind
placebocontrolledstudiesareneededtoassesstowhatextent
melatonin has therapeutic value in the treatment of the
several disorders associated with mitochondrial dysfunction.
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